Physician profile
Ria Itty
NPI 1770967275
$5,601.72
in general payments reported to CMS, 2019-2025
21 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $202 · 2021: $238 · 2022: $2,415 · 2023: $480 · 2024: $852 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,587 · Education: $51.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.70 |
| Education | $51.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,029.72 | 2022 | |
| Glaxosmithkline, LLC. | $1,152.41 | 2020-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $678.71 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $312.37 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.70 | 2022-2025 | Ofev, Stiolto Respimat, Jascayd |
| Amgen INC. | $196.29 | 2024-2025 | Tezspire |
| Mylan Specialty L.P. | $189.56 | 2022-2024 | Yupelri |
| Insmed, INC. | $151.37 | 2021-2025 | Brinsupri, Arikayce |
| Intuitive Surgical, INC. | $123.76 | 2024 | |
| Genentech USA, INC. | $108.80 | 2019 | |
| Grifols USA, LLC | $107.94 | 2022-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $66.24 | 2025 | Yupelri |
| Getinge USA Sales, LLC | $51.00 | 2021 | |
| Verona Pharma, INC. | $45.94 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $41.71 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.21 | 2025 | Winrevair, Zerbaxa |
| Astrazeneca Pharmaceuticals Lp | $33.52 | 2025 | Fasenra |
| Abiomed | $28.02 | 2022-2023 | Impella |
| United Therapeutics Corporation | $18.27 | 2023 | Tyvaso |
| Philips North America LLC | $14.35 | 2024 | (Ak6) Vest Therapy |
| La Jolla Pharmaceutical Company | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ria Itty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.